Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 26 years of covering Asia Pacific equities, the past 20 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Pharma play <strong><a href="https://www.smartkarma.com/entities/simcere-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:29186:1" rel="noopener">Simcere Pharmaceutical (2096 HK)</a></strong> has announced the spin-off and listing of 83.1%-held <strong>Simcere Zaiming</strong> on the HKEx.</li>
<li>There will be a global offering, the details of which are still to be fleshed out. Simcere Pharma is expected to hold &gt;50% in Simcere Zaiming post listing.</li>
<li>Simcere Zaiming, a biopharmaceutical play focusing on oncology, accounted for ~20% of Simcere Pharma's revs in 2024, and ~23% of NTA.</li>
</ul>


Pharma play Simcere Pharmaceutical (2096 HK) has announced the spin-off and listing of 83.1%-held Simcere Zaiming on the HKEx.
There will be a global offering, the details of which are still to be fleshed out. Simcere Pharma is expected to hold &gt;50% in Simcere Zaiming post listing.
Simcere Zaiming, a biopharmaceutical play focusing on oncology, accounted for ~20% of Simcere Pharma's revs in 2024, and ~23% of NTA.


Simcere Pharma (2096 HK)'s Spin-Off and Listing Of Simcere Zaiming